BIOLASE (NASDAQ:BIOL) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the medical technology company’s stock.

Several other analysts also recently issued reports on BIOL. Benchmark reissued a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a research note on Wednesday, October 2nd. Ascendiant Capital Markets lowered their target price on BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.

BIOLASE Stock Performance

BIOL stock opened at $0.01 on Wednesday. The business’s 50-day moving average price is $0.02 and its two-hundred day moving average price is $0.07. The firm has a market cap of $183,738.50, a PE ratio of 0.00 and a beta of 0.67. BIOLASE has a 1-year low of $0.02 and a 1-year high of $1.94.

Institutional Trading of BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC lifted its stake in BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the quarter. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 as of its most recent SEC filing. 8.79% of the stock is currently owned by hedge funds and other institutional investors.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.